Ep. 182 GLP-1 Drugs - One Thing They Don't Reduce
About this episode
The episode discusses the impact of GLP-1 drugs on diabetes and obesity management, highlighting their effectiveness and the lack of reduction in overall health care spending in the short run.
GLP-1 drugs like Ozempic and Wegovy have revolutionized the management of diabetes and obesity. Millions of Americans are experimenting with them. Celebrities like Oprah are sharing their experiences. Duke Sanford School of Public Policy faculty member Jonathan Zhang is an economist who works on health policy, health economics and public finance. His research shows that GLP-1 drugs live up to their promise in everyday medical care. But the study also finds that , at least in the short run, they do not reduce overall health care spending.
More episodes of Policy 360
- Ep. 181 What Jamaican Sprinters Can Teach Us About Upward Mobility
- Ep. 180 Trust & Leadership: A Conversation with CQ Brown, Jr. Former Chairman of the Joint Chiefs of Staff
- Ep. 179 Power to the Renters: Tenant's Rights in a Landlord's World
- Ep. 178 The Hidden Everyday Successes of Government - And How That Can Help Democracy
- Ep. 177 Workers: a non-compete clause should give you pause
- Ep. 176 A Conversation with the 16th Administrator of the EPA Michael Regan
Explore listener stats, chart rankings, contacts and more on the Policy 360 podcast page.